A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (alone or with Pioglitazone and/or SGLT2 inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period

Trial Profile

A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (alone or with Pioglitazone and/or SGLT2 inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Albiglutide; Dulaglutide; Exenatide; Liraglutide; Metformin; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LixiLan-G
  • Sponsors Sanofi
  • Most Recent Events

    • 13 Jul 2017 Planned End Date changed from 1 Oct 2018 to 27 Jun 2018.
    • 13 Jul 2017 Planned primary completion date changed from 4 Apr 2018 to 27 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top